These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1773825)

  • 1. Cardiovascular effects of E4080, a novel bradycardiac agent with coronary vasodilating properties, in anesthetized dogs.
    Kawamura T; Adachi H; Ogawa T
    Eur J Pharmacol; 1991 Oct; 203(3):399-404. PubMed ID: 1773825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition by E4080, a novel bradycardic agent, of positive chronotropic responses to norepinephrine in isolated dog hearts.
    Sawaki S; Furukawa Y; Inoue Y; Oguchi T; Chiba S
    Eur J Pharmacol; 1993 Dec; 250(2):253-9. PubMed ID: 7509284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of E4080, a novel bradycardic agent with a coronary vasodilating property, on coronary and systemic hemodynamics in conscious dogs.
    Adachi H
    J Pharmacol Exp Ther; 1994 Jan; 268(1):133-8. PubMed ID: 8301548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E4080 has a dual action, as a K+ channel opener and a Ca2+ channel blocker, in canine coronary artery smooth muscle.
    Okada Y; Yanagisawa T; Taira N
    Eur J Pharmacol; 1992 Aug; 218(2-3):259-64. PubMed ID: 1330597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of a novel antianginal agent, E4080, on ST segment elevation induced by vasopressin in anesthetized guinea pigs.
    Kodama K; Adachi H; Ogawa T; Ohhara H
    Jpn J Pharmacol; 1992 Oct; 60(2):73-7. PubMed ID: 1479745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glibenclamide prevents coronary vasodilation induced by beta 1-adrenoceptor stimulation in dogs.
    Narishige T; Egashira K; Akatsuka Y; Imamura Y; Takahashi T; Kasuya H; Takeshita A
    Am J Physiol; 1994 Jan; 266(1 Pt 2):H84-92. PubMed ID: 7905717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein.
    Kamouchi M; Xiong Z; Teramoto N; Kajioka S; Okabe K; Kitamura K
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1396-403. PubMed ID: 1762086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of YM099, a novel K+ channel opener, in anesthetized and conscious dogs.
    Uchida W; Hirano Y; Taguchi T; Masuda N; Shirai Y; Satoh N; Takenaka T
    Eur J Pharmacol; 1994 Nov; 264(3):285-93. PubMed ID: 7698167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y; Kawada M; Sawanobori K; Sonoki H; Inoue K; Mizuno K; Itou T; Tabunoki Y; Tsukamoto M; Ohashi Y; Kyotani Y; Shimizu N; Fujii M; Nakamura M
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of K+ATP channels in local metabolic coronary vasodilation.
    Richmond KN; Tune JD; Gorman MW; Feigl EO
    Am J Physiol; 1999 Dec; 277(6):H2115-23. PubMed ID: 10600828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular pharmacological studies on JTV-506, a new potassium channel opener. 1st communication: effects on myocardium and vasculature.
    Hirata Y; Suzuki Y; Miyai H; Aisaka K
    Arzneimittelforschung; 2000 Mar; 50(3):236-43. PubMed ID: 10758774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glibenclamide, a putative ATP-sensitive K+ channel blocker, inhibits coronary autoregulation in anesthetized dogs.
    Narishige T; Egashira K; Akatsuka Y; Katsuda Y; Numaguchi K; Sakata M; Takeshita A
    Circ Res; 1993 Oct; 73(4):771-6. PubMed ID: 8370126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
    Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T
    Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose-dependent effect of amrinone on hemodynamics, myocardial circulation and myocardial energy requirement. An experimental study].
    Veit S; Brückner JB; Vogt K; Wagner R; Hess W
    Z Kardiol; 1985 Feb; 74(2):76-84. PubMed ID: 3993153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.
    Liu Q; Nakae I; Takahashi M; Takaoka A; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Mar; 10(1):23-30. PubMed ID: 8723167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of K+ATP channel and adenosine receptor blockade during rest and exercise in congestive heart failure.
    Traverse JH; Chen Y; Hou M; Li Y; Bache RJ
    Circ Res; 2007 Jun; 100(11):1643-9. PubMed ID: 17478726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75).
    Taira N; Satoh K; Yanagisawa T; Imai Y; Hiwatari M
    Clin Exp Pharmacol Physiol; 1979; 6(3):301-16. PubMed ID: 157241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.
    Kopia GA; Ohlstein EH; Ruffolo RR
    J Pharmacol Exp Ther; 1988 Aug; 246(2):434-40. PubMed ID: 3404441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.